Üyelik Başvurusu   Şifremi Unuttum

 
Ana Sayfa  English  İletişim  
Dernek Görüşleri
Linkler
       [ ]
Dokümanların tamamına ulaşmak için tıklayınız.





 
  Haberler
 

11 Aralık 2014

Hintli firma GVK suçlanırken, Alman Otoritesi BfArM ilaçları piyasadan çekiyor... SocialDoctors İçerisinde Paylaş

GVK Biosciences review: some Member States suspend marketing authorisations for concerned medicines
Update on review of studies performed at GVK Biosciences site in Hyderabad, India

Some Member States have decided to suspend the marketing authorisations of medicines that have been authorised on the basis of studies conducted at the GVK Biosciences site in Hyderabad, India.

The European Medicines Agency (EMA) is currently reviewing findings of non-compliance with good clinical practice at this site and determining their impact on medicines authorised on the basis of studies performed at the site. These suspensions taken at national level are precautionary measures until the review is finalised.

EMA started the review in September 2014 following an inspection carried out by the French medicines agency at the GVK Biosciences site which raised concerns about the reliability of studies conducted at the site between 2008 and 2014.

As part of the review, the EMA’s Committee for Medicinal Products for Human Use (CHMP) is identifying, together with Member States of the European Union (EU), which medicines are affected by the inspection findings. The review will provide a robust scientific assessment of all data and determine the impact of the findings on the concerned medicines, enabling Member States to take adequate EU- wide action to protect patients’ health.

EMA will issue a recommendation on whether the marketing authorisations of the concerned medicines should be maintained, varied, suspended or withdrawn across the EU. The recommendation is expected in January 2015. Detailed information on the ongoing review is available on the EMA website.

Notes

  1. This press release, together with all related documents, is available on the Agency's website.

  2. EU legislation gives Member States the possibility to take precautionary or temporary measures while reviews are ongoing at the EU or national level.

30 Churchill Place Canary Wharf London E14 5EU United Kingdom
Telephone +44 (0)20 3660 8427 Facsimile +44 (0)20 3660 5555
E-mail press@ema.europa.eu Website www.ema.europa.eu An agency of the European Union

page1image18800 page1image18960 page1image19120 page1image19280

3. More information on the work of the European Medicines Agency can be found on its website:

www.ema.europa.eu

Contact our press officer

Monika Benstetter
Tel. +44 (0)20 3660 8427 E-mail:
press@ema.europa.eu

page2image3112 page2image3272 page2image3432

« Geri

Klinik Araştırmalar Derneği © 2006-2007 PLEKSUS